Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2019-06-25 Transaction in Own Shar…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Transaction in Own Shares Classification · 98% confidence The document explicitly details 'Disclosure of transactions in own shares' over a specific period (June 18 to June 21, 2019), presenting aggregated data on volume and price for these transactions. This directly corresponds to the definition of 'Transaction in Own Shares' (share repurchase/issuance). The filing type code for this activity is POS.
2019-06-25 English
Informations privilégiées / Autres communiqués
Transaction in Own Shares Classification · 99% confidence The document is a press release announcing that Ipsen has initiated a share buyback program ('rachat d'actions') to cover a new free share award plan for employees. The key action described is the repurchase of company shares. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS), which covers share repurchase or issuance activities.
2019-06-18 French
Inside Information / Other news releases
Transaction in Own Shares Classification · 99% confidence The document is titled "Ipsen initiates a share buyback program to cover its new free share allocation plan." The text explicitly states that the company has appointed a provider to purchase 150,000 Ipsen SA shares to cover a free employee share allocation plan. This action directly relates to the company managing its own stock, which falls under the definition of 'Transaction in Own Shares' (share repurchase/issuance). This matches code POS. The document length is short (2328 chars), but it is a direct announcement of the transaction, not an announcement *about* a report, so RPA/RNS is less appropriate than the specific POS code.
2019-06-18 English
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Share Issue/Capital Change Classification · 95% confidence The document explicitly states it provides 'Monthly information regarding the total number of voting rights and total number of shares of the Company' under the regulation of the Autorité des Marchés Financiers (AMF). This type of regular disclosure concerning the capital structure, specifically voting rights, does not fit neatly into the primary financial report categories (10-K, IR, ER). It is a specific regulatory disclosure about the share count and voting power. While it relates to capital structure, it is not a financing announcement (CAP) or a director's dealing (DIRS). Given the specific nature of reporting total voting rights monthly, and the lack of a dedicated code for 'Voting Rights Disclosure', the most appropriate general regulatory filing category is Regulatory Filings (RNS), as it is a mandatory, periodic regulatory update that doesn't match the other specific definitions.
2019-06-17 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the total number of shares and voting rights as of May 31, 2019. This content directly relates to the structure of the share capital and voting rights, which aligns best with the 'Share Issue/Capital Change' (SHA) category, as it reports on the composition of the capital and voting rights, even if it's a periodic update. While it is a periodic report, it is not a comprehensive financial report (IR/10-K) or a dividend notice (DIV). It is a specific disclosure about the capital structure.
2019-06-17 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release dated June 12, 2019, announcing the extension of a strategic partnership between Debiopharm and Ipsen regarding the drug Decapeptyl®. It details business strategy, collaboration terms, and includes forward-looking statements and contact information. This type of announcement, which is a general business update concerning strategic agreements rather than a mandatory financial filing (like 10-K, ER, or IR), fits best under the general 'Regulatory Filings' category (RNS) as a miscellaneous corporate announcement, or potentially 'Capital/Financing Update' (CAP) if the partnership renewal involved significant financial restructuring, but given the focus on partnership extension and product development, RNS is the most appropriate general catch-all for non-standard regulatory news releases.
2019-06-12 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.